Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
Table 3.1 is amended as follows:
the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:
Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 |
Ox. Liq. 2
Skin Corr. 1A
H272
H314
GHS03
GHS05
Dgr
H272
H314
EUH071 |
Skin Corr. 1A; H314: C ≥ 20 %
Skin Corr. 1B; H314: 5 % ≤ C < 20 %
Ox. Liq. 2; H272: C ≥ 99 %
Ox. Liq. 3; H272: 99 % > C ≥ 65 %
B
015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 |
Water-react. 1
Acute Tox. 2
Acute Tox. 3
Acute Tox. 1
Eye Dam. 1
Aquatic Acute 1
H260
H300
H311
H330
H318
H400
GHS02
GHS06
GHS05
GHS09
Dgr
H260
H300
H311
H330
H318
H400
EUH029
EUH032
M = 100 |
031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 |
Repr. 1B
Carc. 1B
STOT RE 1
H360F
H350
H372 (respiratory and haematopoietic systems)
GHS08
Dgr
H360F
H350
H372 (respiratory and haematopoietic systems)
050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — |
Repr. 1B
Acute Tox. 3
Acute Tox. 4*
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H360FD
H301
H312
H372**
H315
H319
H400
H410
GHS08
GHS06
GHS09
Dgr
H360FD
H301
H312
H372**
H315
H319
H410
*
STOT RE 1; H372: C ≥ 1 %
STOT RE 2; H373: 0,25 % ≤ C < 1 %
Skin Irrit. 2; H315:C ≥ 1 %
Eye Irrit. 2; H319:C ≥ 1 %
M = 10
A
1
603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 |
Flam. Liq. 2
Carc. 2
Acute Tox. 4*
Acute Tox. 4*
Acute Tox. 4*
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
H225
H351
H302
H312
H332
H335
H315
H319
GHS02
GHS08
GHS07
Dgr
H225
H351
H302
H312
H332
H335
H315
H319
603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 |
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H361d***
H302
H400
H410
GHS08
GHS07
GHS09
Wng
H361d***
H302
H410
M = 1
M = 10
606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 |
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d***
H400
H410
GHS08
GHS09
Wng
H361d***
H410
M = 10
M = 100
607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 |
Skin Irrit. 2
Eye Irrit. 2
Aquatic Chronic 3
H315
H319
H412
GHS07
Wng
H315
H319
H412
613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 |
Carc. 2
Acute Tox. 3
Acute Tox. 4
Eye Dam. 1
Aquatic Chronic 1
H351
H301
H332
H318
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H351
H301
H332
H318
H410
M = 10 |
613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 |
Repr. 2
STOT RE 2
Skin Corr. 1C
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H361d
H373 (liver)
H314
H317
H400
H410
GHS08
GHS05
GHS07
GHS09
Dgr
H361d
H373 (liver)
H314
H317
H410
EUH071 |
M = 1
M = 1
613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 |
Carc. 2
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H317
H410
M = 1
M = 1
613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 |
Acute Tox. 3
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H331
H301
H400
H410
GHS06
GHS09
Dgr
H331
H301
H410
M = 1000
M = 1000
the following entries are inserted in accordance with the order of the entries set out in Table 3.1:
Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors | Notes
Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)
019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Eye Irrit. 2 | H319 |
GSH07
Wng
H319 | | |
604-092-00-9 |
phenol, dodecyl-, branched [1];
phenol, 2-dodecyl-, branched;
phenol, 3-dodecyl-, branched;
phenol, 4-dodecyl-, branched;
phenol, (tetrapropenyl) derivatives [2]
310-154-3 [1] |
121158-58-5 [1]
74499-35-7 [2]
Skin Corr. 1C
Aquatic Acute 1
Aquatic Chronic 1
H314
H400
H410
GHS05
GHS09
Dgr
H314
H410
M = 10
M = 10
606-148-00-8 |
carvone (ISO);
2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]
d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]
l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]
202-759-5 [1]
218-827-2 [2]
229-352-5 [3]
99-49-0 [1]
2244-16-8 [2]
6485-40-1 [3]
Skin Sens. 1 | H317 |
GHS07
Wng
H317 | | |
606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | — | 335104-84-2 |
Repr. 2
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H361d
H373 (eyes, kidneys, liver)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361d
H373 (eyes, kidneys, liver)
H317
H410
M = 100
M = 10
607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 |
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373 (kidneys)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373 (kidneys)
H317
H410
M = 1
M = 1
607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 |
Skin Corr. 1C
Aquatic Chronic 3
H314
H412
GHS05
Dgr
H314
H412
607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 |
Skin Irrit. 2
Eye Irrit. 2
Aquatic Chronic 3
H315
H319
H412
GHS07
Wng
H315
H319
H412
607-710-00-5 | 1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. 1B | H360FD |
GHS08
Dgr
H360FD | | |
607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 |
Repr. 2
STOT SE 3
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H335
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361fd
H335
H319
H317
H410
M = 1
M = 1
607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 |
Repr. 2
STOT RE 2
Skin Corr. 1C
Skin Sens. 1A
Aquatic Chronic 1
H361d
H373 (liver)
H314
H317
H410
GHS08
GHS05
GHS07
GHS09
Dgr
H361d
H373 (liver)
H314
H317
H410
EUH071 | M = 1 |
607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 |
Acute Tox. 3
Acute Tox. 2
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H301
H330
H317
H400
H410
GHS06 GHS09
Dgr
H301
H330
H317
H410
M = 100
M = 1000
607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 |
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 100
M = 10
607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 |
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373
H317
H410
M = 1
M = 1
613-319-00-0 | imidazole | 206-019-2 | 288-32-4 |
Repr. 1B
Acute Tox. 4
Skin Corr. 1C
H360D
H302
H314
GHS08
GHS07
GHS05
Dgr
H360D
H302
H314
613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 |
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 10
M = 10
616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 |
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 | |
M = 1
M = 1
616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 |
Carc. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H373 (eyes, kidneys)
H400
H410
GHS08
GHS09
Wng
H351
H373 (eyes, kidneys)
H410
M = 1000
M = 100
616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 |
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H317
H400
H410
GHS07
GHS09
Wng
H302
H317
H410
M = 10
M = 10
616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Acute Tox. 4 | H302 |
GHS07
Wng
H302 | | |
616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 |
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
M = 1
M = 1
Table 3.2 is amended as follows:
the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:
Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes
007-004-00-1 | nitric acid … % | 231-714-2 | 7697-37-2 |
O; R8
C; R35
O; C
R: 8-35
S: (1/2-)26-28- 36/37/39-45-63
O; R8: C ≥ 65 %
C; R35: C ≥ 20 %
C; R34: 5 % ≤ C < 20 %
B
015-003-00-2 | calcium phosphide; tricalcium diphosphide | 215-142-0 | 1305-99-3 |
F; R15/29
T+; R26/28
Xn; R21
R32
Xi; R38-41
N; R50
F; T+; N
R: 15/29-21-26/28-32-38-41-50
S:(1/2-)26-28-30-36/37/39-43-45-60-61
N; R50: C ≥ 0,25 % |
031-001-00-4 | gallium arsenide | 215-114-8 | 1303-00-0 |
Repr. Cat. 2; R60
Carc. Cat. 2; R45
T; R48/23
T
R: 45-48/23-60
S: 45-53
E
050-008-00-3 | tributyltin compounds, with the exception of those specified elsewhere in this annex | — | — |
Repr. Cat. 2; R60-61
T; R25-48/23/25
Xn; R21
Xi; R36/38
N; R50-53
T; N
R: 21-25-36/38-48/23/25-50/53-60-61
S: 45-53-60-61
T; R25: C ≥ 2,5 %
Xn; R22: 0,25 % ≤ C < 2,5 %
Xn: R21: C ≥ 1 %
T; R48/23/25: C ≥ 1 %
Xn; R48/20/22: 0,25 % ≤ C < 1 %
Xi; R36/38: C ≥ 1 %
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
A
1
603-102-00-9 | 1,2-epoxybutane | 203-438-2 | 106-88-7 |
F; R11
Carc. Cat. 3; R40
Xn; R20/21/22
Xi; R36/37/38
F; Xn
R: 11-20/21/22-36/37/38-40-
S: (2-)9-16-29-36/37-46
603-197-00-7 | tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol | 403-640-2 | 107534-96-3 |
Repr. Cat. 3; R63
Xn; R22
N; R50-53
Xn; N
R: 22-50/53-63
S: (2-)22-36/37-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C <25 %
R52-53: 0,25 % ≤ C < 2,5 %
606-054-00-7 | isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone | — | 141112-29-0 |
Repr. Cat. 3; R63
N; R50-53
Xn; N
R: 50/53-63
S: (2-)36/37-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
607-197-00-8 | nonanoic acid | 203-931-2 | 112-05-0 |
Xi; R36/38
N; R51-53
Xi; N
R: 36/38-51/53
S: (2-)46-61
613-042-00-5 | imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole | 252-615-0 | 35554-44-0 |
Carc. Cat. 3; R40
Xn; R20/22
Xi; R41
N; R51-53
Xn; N
R: 20/22-40-41-51/53
S: (2-)26-36/37/39-46-61
613-057-00-7 | dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine | 216-474-9 | 1593-77-7 |
Repr. Cat. 3; R63
C; R34
R43
N; R50-53
C; N
R: 34-43-50/53-63
S: (1/2-)26-28-36/37/39-45-60-61
C; R34: C ≥ 10 %
Xi; R36/37/38: 5 % ≤ C < 10 %
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-133-00-X | etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole | 219-991-8 | 2593-15-9 |
Carc. Cat. 3; R40
Xn; R22
R43
N; R50-53
Xn; N
R: 22-40-43-50/53
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-149-00-7 | pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one | 405-700-3 | 96489-71-3 |
T; R23/25
N; R50-53
T; N
R: 23/25-50/53
S: (1/2-)36/37-45-60-61
N; R50-53: C ≥ 0,025 %
N; R51-53: 0,0025 % ≤ C < 0,025 %
R52-53: 0,00025 % ≤ C < 0,0025 %
the following entries are inserted in accordance with the order of the entries set out in Table 3.2:
Index No | International Chemical Identification | EC No | CAS No | Classification | Labelling | Concentration Limits | Notes
019-003-00-3 | potassium (E,E)-hexa-2,4-dienoate | 246-376-1 | 24634-61-5 | Xi; R36 |
Xi
R: 36
S: (2-)25-46
604-092-00-9 |
phenol, dodecyl-, branched [1];
phenol, 2-dodecyl-, branched;
phenol, 3-dodecyl-, branched;
phenol, 4-dodecyl-, branched;
phenol, (tetrapropenyl) derivatives [2]
310-154-3 [1]-[2] |
121158-58-5 [1]
74499-35-7 [2]
C; R34
N; R50-53
C; N
R: 34-50/53
S: (1/2-)26-36/37/39-45-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
606-148-00-8 |
carvone (ISO);
2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]
d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]
l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]
202-759-5 [1]
218-827-2 [2]
229-352-5 [3]
99-49-0 [1]
2244-16-8 [2]
6485-40-1 [3]
R43 |
Xi
R: 43
S: (2-)24-37
606-149-00-3 | tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione | | 335104-84-2 |
Repr. Cat. 3; R63
Xn; R48/22
R43
N; R50-53
Xn; N
R: 43-48/22-50/53-63
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
607-707-00-9 | fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate | — | 71283-80-2 |
Xn; R48/22
R43
N; R50-53
Xn; N
R: 43-48/22-50/53
S: (2-)24-37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
607-708-00-4 | octanoic acid | 204-677-5 | 124-07-2 |
C; R34
N; R51-53
C; N
R: 34-51/53
S: (1/2-)26-36/37/39-45-61
607-709-00-X | decanoic acid | 206-376-4 | 334-48-5 |
Xi; R36/38
N; R51-53
Xi; N
R: 36/38-51/53
S: (2-)25-46-61
607-710-00-5 | 1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear | 271-093-5 | 68515-50-4 | Repr. Cat. 2; R60-61 |
T
R: 60-61
S: 53-45
607-711-00-0 | spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate | — | 203313-25-1 |
Repr. Cat. 3; R62-63
Xi; R36/37
R43
N; R50-53
Xn; N
R: 36/37-43-50/53-62-63
S: (2-)36/37-60-61
Xi; R43: C ≥ 0,1 %
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
607-712-00-6 | dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate | 250-778-2 | 31717-87-0 |
Repr. Cat. 3; R63
C; R34
R43
N; R51-53
C; N
R: 34-43-51/53-63
S: (1/2-)26-28-36/37/39-45-61
C; R34: C ≥ 10 %
Xi: R36/37/38: 5 % ≤ C < 10 %
607-713-00-1 | fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate | — | 134098-61-6 |
T+; R26
Xn; R22
R43
N; R50-53
T+; N
R: 22-26-43-50/53
S: (1/2-)28-36/37-45-60-61-63
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
607-714-00-7 | triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate | — | 126535-15-7 |
Carc. Cat. 3; R40
N; R50-53
Xn; N
R: 40-50/53
S: (2-)36/37-60-61
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
607-715-00-2 | bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate | 442-820-5 | 149877-41-8 |
R43
N; R50-53
Xi; N
R: 43-50/53
S: (2-)24-37-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-319-00-0 | imidazole | 206-019-2 | 288-32-4 |
Repr. Cat 2; R61
Xn; R22
C; R34
T; C
R: 22-34-61
S: 53-45
613-320-00-6 | lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione | 218-499-0 | 2164-08-1 |
Carc. Cat. 3; R40
N; R50-53
Xn; N
R: 40-50/53
S: (2-)36/37-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
616-213-00-2 | mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide | — | 374726-62-2 | N; R50-53 |
N
R: 50/53
S: 60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C <25 %
R52-53: 0,25 % ≤ C < 2,5 %
616-214-00-8 | metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide | — | 139528-85-1 |
Carc. Cat. 3; R40
Xn; R48/22
N; R50-53
Xn; N
R: 40-48/22-50/53
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 0,025 %
N; R51-53: 0,0025 % ≤ C < 0,025 %
R52/53: 0,00025 % ≤ C < 0,0025 %
616-215-00-3 | dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide | — | 163515-14-8 |
Xn; R22
R43
N; R50-53
Xn; N
R: 22-43-50/53
S: (2-)24-37-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
616-216-00-9 | flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide | — | 158062-67-0 | Xn; R22 |
Xn
R: 22
S: (2-)46
616-217-00-4 | sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide | — | 946578-00-3 |
Xn; R22
N; R50-53
Xn; N
R: 22-50/53
S: (2-)60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %